279 related articles for article (PubMed ID: 32008736)
1. [Management of side effects related to adjuvant hormone therapy in young women with breast cancer].
Saghatchian M; Lesur A
Bull Cancer; 2019 Dec; 106(12S1):S37-S42. PubMed ID: 32008736
[TBL] [Abstract][Full Text] [Related]
2. Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients.
Morales L; Neven P; Timmerman D; Christiaens MR; Vergote I; Van Limbergen E; Carbonez A; Van Huffel S; Ameye L; Paridaens R
Anticancer Drugs; 2004 Sep; 15(8):753-60. PubMed ID: 15494636
[TBL] [Abstract][Full Text] [Related]
3. Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer.
Perez EA
Ann Oncol; 2007 Sep; 18 Suppl 8():viii26-35. PubMed ID: 17890211
[TBL] [Abstract][Full Text] [Related]
4. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.
Mouridsen HT
Curr Med Res Opin; 2006 Aug; 22(8):1609-21. PubMed ID: 16870085
[TBL] [Abstract][Full Text] [Related]
5. Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer.
Franzoi MA; Agostinetto E; Perachino M; Del Mastro L; de Azambuja E; Vaz-Luis I; Partridge AH; Lambertini M
Lancet Oncol; 2021 Jul; 22(7):e303-e313. PubMed ID: 33891888
[TBL] [Abstract][Full Text] [Related]
6. Aromatase inhibitor-associated arthralgia syndrome.
Burstein HJ
Breast; 2007 Jun; 16(3):223-34. PubMed ID: 17368903
[TBL] [Abstract][Full Text] [Related]
7. Tamoxifen effects on subjective and psychosexual well-being, in a randomised breast cancer study comparing high-dose and standard-dose chemotherapy.
Mourits MJ; Böckermann I; de Vries EG; van der Zee AG; ten Hoor KA; van der Graaf WT; Sluiter WJ; Willemse PH
Br J Cancer; 2002 May; 86(10):1546-50. PubMed ID: 12085202
[TBL] [Abstract][Full Text] [Related]
8. Specific adverse events predict survival benefit in patients treated with tamoxifen or aromatase inhibitors: an international tamoxifen exemestane adjuvant multinational trial analysis.
Fontein DB; Seynaeve C; Hadji P; Hille ET; van de Water W; Putter H; Kranenbarg EM; Hasenburg A; Paridaens RJ; Vannetzel JM; Markopoulos C; Hozumi Y; Bartlett JM; Jones SE; Rea DW; Nortier JW; van de Velde CJ
J Clin Oncol; 2013 Jun; 31(18):2257-64. PubMed ID: 23610112
[TBL] [Abstract][Full Text] [Related]
9. The influence of endocrine treatments for breast cancer on health-related quality of life.
Buijs C; de Vries EG; Mourits MJ; Willemse PH
Cancer Treat Rev; 2008 Nov; 34(7):640-55. PubMed ID: 18514425
[TBL] [Abstract][Full Text] [Related]
10. The impact of endocrine therapy on sexual dysfunction in postmenopausal women with early stage breast cancer: encouraging results from a prospective study.
Frechette D; Paquet L; Verma S; Clemons M; Wheatley-Price P; Gertler SZ; Song X; Graham N; Dent S
Breast Cancer Res Treat; 2013 Aug; 141(1):111-7. PubMed ID: 23942873
[TBL] [Abstract][Full Text] [Related]
11. Testing a behavioral intervention to improve adherence to adjuvant endocrine therapy (AET).
Shelby RA; Dorfman CS; Bosworth HB; Keefe F; Sutton L; Owen L; Corsino L; Erkanli A; Reed SD; Arthur SS; Somers T; Barrett N; Huettel S; Gonzalez JM; Kimmick G
Contemp Clin Trials; 2019 Jan; 76():120-131. PubMed ID: 30472215
[TBL] [Abstract][Full Text] [Related]
12. Managing side effects in adjuvant endocrine therapy for breast cancer.
Condorelli R; Vaz-Luis I
Expert Rev Anticancer Ther; 2018 Nov; 18(11):1101-1112. PubMed ID: 30188738
[TBL] [Abstract][Full Text] [Related]
13. [New options in adjuvant endocrine therapy in breast cancer].
Saltel-Fulero A; Donnadieu A; Leman-Detours S; Cottu P
Bull Cancer; 2016 Jan; 103(1):104-12. PubMed ID: 26675809
[TBL] [Abstract][Full Text] [Related]
14. Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B.
Fallowfield LJ; Leaity SK; Howell A; Benson S; Cella D
Breast Cancer Res Treat; 1999 May; 55(2):189-99. PubMed ID: 10481946
[TBL] [Abstract][Full Text] [Related]
15. [Optimal adjuvant hormone therapy in postmenopausal women with hormone-sensitive mammary carcinoma: tamoxifen and the aromatase inhibitors anastrozole, exemestane and letrozole].
van Nes JG; Seynaeve C; van de Velde CJ; Nortier JW
Ned Tijdschr Geneeskd; 2006 Dec; 150(52):2863-9. PubMed ID: 17319217
[TBL] [Abstract][Full Text] [Related]
16. Clinical utility of genetic signatures in selecting adjuvant treatment: Risk stratification for early vs. late recurrences.
Hayes DF
Breast; 2015 Nov; 24 Suppl 2():S6-S10. PubMed ID: 26238437
[TBL] [Abstract][Full Text] [Related]
17. Side effects of aromatase inhibitors versus tamoxifen: the patients' perspective.
Garreau JR; Delamelena T; Walts D; Karamlou K; Johnson N
Am J Surg; 2006 Oct; 192(4):496-8. PubMed ID: 16978958
[TBL] [Abstract][Full Text] [Related]
18. Overview of long term care of breast cancer survivors.
Brennan ME; Houssami N
Maturitas; 2011 Jun; 69(2):106-12. PubMed ID: 21489727
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of menopausal symptoms and their influence on adherence in women with breast cancer.
Kyvernitakis I; Ziller V; Hars O; Bauer M; Kalder M; Hadji P
Climacteric; 2014 Jun; 17(3):252-9. PubMed ID: 23805799
[TBL] [Abstract][Full Text] [Related]
20. Aromatase inhibitors and musculoskeletal symptoms.
Khanduri S; Dodwell DJ
Breast; 2008 Feb; 17(1):76-9. PubMed ID: 17822901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
